Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The methylation ratios for the three genes were significantly higher in LC than in MPM (RASSF1A, P = 0.039; p16(INK4a), P = 0.005; and RARβ, P = 0.002).
|
22146010 |
2012 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positive rates of MAGE A1-A6 RT-PCR, MAGE A3 MSP and p16 MSP were as follows: in lung cancer tissue, 87.5, 58.3 and 70.8%; in the sputum of lung cancer patients, 50.8, 46.2 and 63.1%; benign lung diseases, 10.3, 30.9 and 39.7%; and healthy individuals, 3.3, 6.7 and 3.3%.
|
22134685 |
2012 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
These results demonstrate that the suppression of p16Ink4a by either the induction of Bmi-1 or the hypermethylation of p16Ink4 may be an important step in avoiding tumor surveillance by p38 MAPK during the development of lung cancer.
|
21164364 |
2011 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This may suggest that TP53 mutation and CDKN2A methylation specifically interact to promote lung tumorigenesis in subjects with CYP1A1 risk genotype but not in those with CYP1A1 wild-type homozygotes, implying different pathways for the development of lung carcinoma with respect to CYP1A1 polymorphism.
|
22154617 |
2011 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our previous study showed that methylation of p16 gene in chromate lung cancer and nonchromate lung cancer was 33% and 26%, respectively.
|
21229606 |
2011 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The diagnostic sensitivity of MOB was evaluated by methylation analysis of the CDKN2A [cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); also known as p16(INK4a)] promoter in serum DNA of lung cancer patients and compared with that of conventional methods.
|
20360128 |
2010 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibitory effects of p16INK4a, p14ARF and p12 were studied in the human lung cancer cell line A549 which lacks the CDKN2A locus.
|
20565749 |
2010 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed a high frequency of losses of the p16 - in 8/18 (44%) - and p53 - in 7/18 (39%) - genes in the cases with LC.
|
20444664 |
2010 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to investigate the mechanism of P16/CDKN2A alterations in lung cancer in asbestos-exposed patients.
|
19375815 |
2010 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed that zebularine treatment resulted in inhibition of cell growth in 11 out of 12 lung cancer cell lines with silenced CDKN2A, but no cell growth inhibition was detected in the 7 lung cancer cell lines tested with deleted CDKN2A (p>0.001).
|
20811718 |
2010 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To explore this issue, we assume (perhaps incorrectly) that arsenic in cigarette smoke increases lung cancer risk by hypermethylating the promoter region of gene p16INK4a, leading to a more rapid entry of altered (initiated) cells into a clonal expansion phase.
|
19000069 |
2009 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DUSP4 loss also associates with p16/CDKN2A deletion and defines a distinct clinical subset of lung cancer patients.
|
19525976 |
2009 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hoechst staining, cell proliferation and TUNEL assays, real-time quantitative PCR, Western blotting, chromatin immunoprecipitation and RNA interference were employed in investigating the role of induction of p14ARF by E2F1 in 8-Cl-Ado-induced apoptosis in human lung cancer H1299 cells.
|
19641316 |
2009 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of p16INK4a expression has also been frequently observed in more common neoplasms such as lung cancer as well.
|
18379362 |
2008 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, the p16 gene was affected by promoter methylation at a frequency even higher among the lung cancer group, compared with the noncancer group [70.7% (41/58) versus 51.7% (55/107), p = 0.017].
|
18751376 |
2008 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Determine 62 NSCLC tumor tissues (5 years ago) and p14(ARF) expression with immunohistochemical technique, discuss the correlation between them and assess the effect of Pokemon on prognosis of patients with lung cancer.
|
18550205 |
2008 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Beside CDKN2A, other genes (e.g., CDKN2B, and ARF/p14(ARF), long considered distinct from CDKN2A) on this locus are often deleted or mutated in a large number of tumors including glioma, bladder cancer, and lung cancer.
|
18406873 |
2008 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of p16 and ESR1 promoter methylation in blood using real-time PCR appears to be very useful for lung cancer diagnosis and there is some possibility that these methylated genes might come to represent useful biomarkers for the early detection of lung cancer.
|
18949413 |
2008 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.
|
17936562 |
2007 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of DeltaDNMT3B4 expression by small interfering RNA resulted in a rapid demethylation of RASSF1A promoter and reexpression of RASSF1A mRNA but had no effect on p16 promoter in the lung cancer cells.
|
18006804 |
2007 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Promoter hypermethylation of the p16(INK4a) gene was investigated in 81 sets of samples of tumor tissue and adjacent normal tissue from Korean patients with primary lung cancer, using the modified real-time polymerase chain reaction (PCR)/ SYBR Green detection method.
|
17923752 |
2007 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Multiple logistic regression analysis showed that the odds ratio for having lung cancer was 10.204 for individuals with p16 methylation (P = .013) and 9.952 for individuals with RASSFIA methylation (P = .019).
|
17876837 |
2007 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, the frequency of p16 methylation in chromate lung cancer was constant, irrespective of the Brinkman index.
|
16828922 |
2006 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
As some of these alterations, such as p16INK4A methylation, can also be detected in bronchial lavage and serum, they could potentially serve as useful markers for the early detection of lung cancer.
|
16613540 |
2006 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we hypothesized that the genetic variants in these three genes influence the predisposition of lung cancer (i.e., CCND1 G870A, CDKN2A Ala(148)Thr, TP53 Arg(72)Pro, and 16-bp repeat in intron 3) and that the effect of X-ray on lung cancer risk can be modified by the presence of these genetic variations.
|
16912209 |
2006 |